Opiant Pharmaceuticals (NASDAQ:OPNT) posted its quarterly earnings results on Tuesday, November 12th. The technology company reported $1.97 EPS for the quarter, beating the consensus estimate of $0.10 by $1.87, Fidelity Earnings reports. The firm had revenue of $20.64 million during the quarter, compared to analysts’ expectations of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%.
NASDAQ OPNT traded up $1.04 during trading on Friday, reaching $14.20. 17,399 shares of the company’s stock were exchanged, compared to its average volume of 23,974. The company has a 50 day moving average price of $14.75 and a two-hundred day moving average price of $13.76. The stock has a market cap of $53.99 million, a P/E ratio of -2.00 and a beta of 0.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.28 and a current ratio of 4.28. Opiant Pharmaceuticals has a 1 year low of $9.98 and a 1 year high of $18.23.
Several equities research analysts have issued reports on OPNT shares. TheStreet raised Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research note on Friday, August 30th. Northland Securities reissued a “buy” rating and set a $42.00 target price on shares of Opiant Pharmaceuticals in a research note on Thursday, November 7th.
In other Opiant Pharmaceuticals news, Director Michael Sinclair sold 60,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $12.52, for a total transaction of $751,200.00. Also, insider Phil Skolnick sold 10,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $15.80, for a total value of $158,000.00. In the last ninety days, insiders sold 90,000 shares of company stock worth $1,197,500. 30.88% of the stock is owned by corporate insiders.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More: What are different types of coverage ratios?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.